1. Home
  2. SENEA vs OMER Comparison

SENEA vs OMER Comparison

Compare SENEA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seneca Foods Corp.

SENEA

Seneca Foods Corp.

HOLD

Current Price

$173.94

Market Cap

908.7M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.55

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENEA
OMER
Founded
1949
1994
Country
United States
United States
Employees
6895
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
908.7M
772.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
SENEA
OMER
Price
$173.94
$9.55
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
162.9K
2.4M
Earning Date
06-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
N/A
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$233.22
P/E Ratio
$13.21
$15.98
Revenue Growth
N/A
N/A
52 Week Low
$98.61
$2.96
52 Week High
$181.43
$17.65

Technical Indicators

Market Signals
Indicator
SENEA
OMER
Relative Strength Index (RSI) 68.12 43.02
Support Level $131.61 $9.12
Resistance Level $181.43 $12.19
Average True Range (ATR) 9.79 0.93
MACD 1.47 0.08
Stochastic Oscillator 78.29 70.87

Price Performance

Historical Comparison
SENEA
OMER

About SENEA Seneca Foods Corp.

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: